期刊
BIOMATERIALS
卷 31, 期 2, 页码 339-344出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2009.09.033
关键词
Drug delivery; Mucus-penetrating particles; Cancer; Controlled release; Biodegradable polymers
资金
- NIH [R21 HL089816]
- Flight Attendant Medical Research Institute
- NSF [GK-12 BIGSTEP]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL089816] Funding Source: NIH RePORTER
Drug carrier particles composed of poly(ethylene glycol)-co-poly(sebacic acid) (PEG-PSA) have been shown capable of efficient aerosolization into model lungs and the ability to rapidly penetrate human mucus. Here, we develop PEG-PSA particles (Etop/PEC-PSA) that encapsulate up to 40% etoposide by weight in a one step process, release it continuously for 6 days in vitro, and maintain its cytotoxic activity against a human lung tumor cell line in vitro. We further show that Etop/PEG-PSA injected intratumorally effectively suppress human lung tumor growth in a xenograft mouse model, with 100% survival after 31 days. In contrast, 0% survival was observed by day 24 in animals that received free etoposide (either intratumoral or intraperitoneal administration) or placebo particles intratumorally. These findings support PEC-PSA as a drug delivery platform for improved local therapy of cancer. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据